Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) – Stock analysts at SVB Leerink lowered their FY2021 earnings estimates for shares of Dicerna Pharmaceuticals in a report issued on Tuesday, November 9th. SVB Leerink analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($1.05) per share for the year, down from their previous forecast of ($0.36). SVB Leerink currently has a “Outperform” rating and a $47.00 target price on the stock. SVB Leerink also issued estimates for Dicerna Pharmaceuticals’ Q4 2021 earnings at $0.09 EPS and FY2022 earnings at ($0.12) EPS.
Several other analysts have also recently weighed in on DRNA. Cowen cut shares of Dicerna Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, August 6th. Chardan Capital reiterated a “buy” rating and issued a $27.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Wednesday. B. Riley dropped their price objective on shares of Dicerna Pharmaceuticals from $49.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, August 11th. Royal Bank of Canada dropped their price objective on shares of Dicerna Pharmaceuticals from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Friday, August 6th. Finally, The Goldman Sachs Group lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $36.00 to $25.00 in a report on Tuesday, August 10th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $32.30.
Shares of Dicerna Pharmaceuticals stock opened at $22.14 on Friday. Dicerna Pharmaceuticals has a twelve month low of $19.06 and a twelve month high of $40.14. The company has a 50-day simple moving average of $21.02 and a two-hundred day simple moving average of $27.79. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -13.02 and a beta of 0.93. Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Tuesday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. Dicerna Pharmaceuticals had a negative net margin of 72.28% and a negative return on equity of 97.72%. During the same quarter in the previous year, the firm posted ($0.29) earnings per share.
Several hedge funds and other institutional investors have recently modified their holdings of DRNA. Close Asset Management Ltd acquired a new position in shares of Dicerna Pharmaceuticals during the 3rd quarter valued at $40,000. Lazard Asset Management LLC bought a new stake in shares of Dicerna Pharmaceuticals in the 2nd quarter worth $93,000. Eaton Vance Management bought a new stake in shares of Dicerna Pharmaceuticals in the 1st quarter worth $67,000. Advisor Group Holdings Inc. grew its stake in shares of Dicerna Pharmaceuticals by 88.3% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,744 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 1,287 shares in the last quarter. Finally, Meeder Asset Management Inc. grew its position in Dicerna Pharmaceuticals by 97.4% during the third quarter. Meeder Asset Management Inc. now owns 4,619 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 2,279 shares during the period. Hedge funds and other institutional investors own 78.91% of the company’s stock.
In related news, insider Ling Zeng sold 1,334 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Friday, September 17th. The shares were sold at an average price of $21.47, for a total transaction of $28,640.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Shreeram Aradhye sold 2,056 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Friday, September 17th. The stock was sold at an average price of $21.47, for a total transaction of $44,142.32. The disclosure for this sale can be found here. Insiders own 10.20% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.